#USA #Staten Island #Acurx Pharmaceuticals #Gut Microbiome #PolC inhibitors

Acurx Pharmaceuticals Unveils Antibiotics Study

Acurx Pharmaceuticals has recently published groundbreaking findings in the Microbiology Spectrum journal, marking a pivotal moment in the quest for innovative antibiotics. The study presents the first direct comparison of the effects of its novel preclinical antibiotics, known as PolC inhibitors, against linezolid, a commonly used treatment for gram-positive bacterial infections. Researchers set out to determine how these experimental drugs might affect the gut microbiome compared to standard treatments.

In this study, Acurx demonstrated that the newly developed PolC inhibitors did not only reduce the burden of methicillin-resistant Staphylococcus aureus (MRSA) in a murine neutropenic thigh infection model, but they also preserved gut microbial diversity. This contrasts sharply with linezolid, which is known to disrupt healthy gut bacteria. The PolC inhibitors maintained anaerobic microbiome components and metabolic function, appearing to offer a microbiome-sparing class effect—a significant advantage in antibiotic therapy.

Significance of the Findings

Principal investigator Kevin Garey, PharmD, emphasized the importance of these results, stating, "Finding highly selective antibacterial agents that avoid destroying the beneficial bacteria in the gut microbiome is the 'Holy Grail' of antibiotic development." This assertion highlights the necessity of developing antibiotics that can effectively combat pathogens while maintaining gut health.

The study's results affirm Acurx's commitment to pioneering a model of antibiotic stewardship that conserves the microbiome. Robert J. DeLuccia, Executive Chairman of Acurx, added, "We're paving the way for a new standard in drug discovery, focusing on minimizing gut dysbiosis caused by antibiotics."

Overview of the Research Methodology

The research team employed a murine model with neutropenic mice, simulating a genuine bacterial infection scenario. They tested various doses of PolC inhibitors along with linezolid and monitored changes in gut microbiome composition. Notably, the novel antibiotics preserved a Bacteroidota-dominant community in the gut, showcasing their potential to be a part of the next generation of therapeutics that take microbiome health into account.

Clinical Implications

Acurx's pipeline focuses on serious bacterial infections classified as serious threats by the CDC, including conditions associated with MRSA, such as acute bacterial skin and skin structure infections and hospital-acquired pneumonia. The findings from this study align with the growing need for antibiotics that can combat resistant strains without the collateral damage to beneficial gut flora.

Additionally, the PolC inhibitors are designated as Qualified Infectious Disease Products (QIDP) and have been given Fast-Track status by the FDA, accelerating their development pathway. Acurx aims to bridge the gap in current treatments, where antibiotics not only need to be effective but also should safeguard gut microbiota—a crucial aspect often overlooked in the drug development process.

Looking Ahead

With emerging threats from antimicrobial resistance, the need for novel antibiotic strategies is dire. The study's promising results position Acurx Pharmaceuticals at the forefront of developing more targeted antibiotics, potentially reshaping how future infectious disease therapies are approached. As they undertake additional trials, the focus on preserving the microbiome while effectively treating infections will likely set new standards within the industry.

For more information on Acurx's research and ongoing efforts in antibiotic development, visit their website at www.acurxpharma.com.

In conclusion, as the battle against antibiotic resistance grows more complex, the research from Acurx Pharmaceuticals sheds light on a hopeful path forward, one that emphasizes both efficacy and the importance of maintaining gut health during treatment.